Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyrophosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | INPP5B | P32019 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL145674 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL17765467 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL1985595 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL9522730 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL4346392 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL28049291 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL933099 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL3788496 | 1.00 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL23410734 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL11522910 | 0.96 | FDPS (0.83) | FDPSBLMTDP1CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKSCI INC. (CA) | 2024-05-21 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2021-10-21 | — | — | US | disclosed |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | 3100 CENTRAL EXPRESSWAY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3700905-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | Allergan, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | NANOSYN, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3600328-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | Nanosyn, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2534137-B1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID-2 AGONISTS | ALLERGAN INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062004-B2 | Cannabinoid-2 agonists | ALLERGAN, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | ALLERGAN, INC (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2534137-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | Allergan, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011097553-A1 | PYRIDAZINE DERIVATIVES USEFUL AS CANNABINOID - 2 AGONISTS | ALLERGAN, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-5338770-A | Anticoagulants; amine-functional siloxanes reacted with polyethers coupled to bioactive material; oxygenators | CARDIOPULMONICS, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| EP-0531305-A4 | GAS PERMEABLE THROMBO-RESISTANT COATINGS AND METHODS OF MANUFACTURE | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0531305-A1 | GAS PERMEABLE THROMBO-RESISTANT COATINGS AND METHODS OF MANUFACTURE | CARDIOPULMONICS, INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991015952-A1 | GAS PERMEABLE THROMBO-RESISTANT COATINGS AND METHODS OF MANUFACTURE | CARDIOPULMONICS, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284400-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | FDPS 1979/4885BLM 4471/4885TDP1 4436/4885 |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | FDPS 1209/4885BLM 950/4885TDP1 340/4885 |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | FDPS 1209/4885BLM 950/4885TDP1 340/4885 |
| US-20130059848-A1 | CANNABINOID-2 AGONISTS | CNR2, CNR1, GPR18 | FDPS 2132/4885BLM 4463/4885TDP1 4505/4885 |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | FDPS 4361/4885BLM 629/4885TDP1 3833/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | FDPS 167/4885BLM 3463/4885TDP1 2788/4885 |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | FDPS 1209/4885BLM 950/4885TDP1 340/4885 |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | FDPS 1209/4885BLM 950/4885TDP1 340/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | FDPS 167/4885BLM 3463/4885TDP1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.